Investing.com -- Moody’s Ratings has affirmed Edwards Lifesciences Corporation ’s Baa2 ratings while revising the outlook to positive from stable, the credit rating agency announced Wednesday.

The data, which will be presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, builds upon earlier results presented at ASCO. The study showed a disease control rate of 93.8% at the ...